51results about How to "Inhibition level" patented technology

The application discloses a vehicle-mounted video image stabilization method. The method comprises: extracting feature points in a video frame sequence; matching each two adjacent frames of feature points in the video frame sequence to obtain a set of matched feature point pairs; calculating a matrix parameter of a camera motion model; calculating a horizontal average motion vector of horizontal displacement A and a vertical average motion vector of vertical displacement; calculating a to-be-filtered horizontal motion vector according to the horizontal average motion vector and calculating a to-be-filtered vertical motion vector according to the vertical average motion vector; and carrying out motion compensation on the video frame sequence by using the a to-be-filtered horizontal motion vector and the to-be-filtered vertical motion vector. Therefore, random jittering between successive frames in a video frame sequence is compensated; horizontal and vertical movements occurring during a video shooting process are suppressed; the moving track of the video frame sequence after image stabilization becomes smooth; the vehicle-mounted video quality is improved; and the post processing of the vehicle-mounted video is realized smoothly.

The invention relates to application of oleanolic acid in preparation of drugs for treatment autoimmune diseases, and belongs to the technical field of biomedicine. The oleanolic acid can inhibit thefunction of the transcription factor ROR[gamma]t, inhibit the differentiation of Th17 cells, and inhibit the transcriptional expression of the target genes IL-17A and IL-17F of ROR[gamma]t at the RNAlevel, and inhibit IL-17A cytokines. The secretion inhibits the level of anti-dsDNA antibodies in the serum; the oleanolic acid of the present invention has an obvious Th17 cell activity inhibitory function, and provides a lead structure for the development of new drugs for the treatment of autoimmune diseases.

The invention relates to a retroviral recombinant capable of efficiently expressing siRNA targeting the ATP binding region of BCRP/ABCG2 gene, which belongs to the field of genetic engineering. Retroviral recombinants are recombined with retroviral RNAi expression system and oligonucleotide fragments, and are packaged by viral packaging cells. The invention is mainly applied to the drug resistance reversal of the breast cancer resistance protein.

The invention discloses novel application of radiation-resistant peptide proteins and provides application of radiation-resistant peptide proteins in preparation of products for inhibiting liver injury diseases. The amino acid sequence of the radiation-resistant peptide proteins refers to a sequence 2 in a sequence table. The experiment proves that the radiation-resistant peptide proteins can inhibit the liver injury and can be used for preparing medicines with the effect of inhibiting the liver injury.

The present invention provides a use of a HIF-2alpha inhibitor in preparation of drugs for preventing and treating acute high-altitude reaction. The HIF-2alpha inhibitor comprises HIF-2alpha-I2 and/orPT2385; the use according to the invention fully investigates molecular mechanisms and key molecular events and processes of acute high-altitude reaction and hypoxia stress, and a series of experiments shows that HIF-2alpha-I2 and PT2385 both can significantly improve the malignant degree and symptoms including slowing shortness of breath, emotional upset, and high heart rate of acute high-altitude reaction, as well as alleviate the acute hypoxic stress response, so as to achieve the purpose of effectively preventing acute hypoxia. The use has good safety, little side effects and other advantages, and has a good application prospect.

The invention relates to a pure traditional Chinese medical compound capsule of climbing entada seed for reducing blood sugar, prepared from raw medicinal materials: climbing entada seed, safflower, common fennel, celery seed, myrobalan and strawflower and assistant materials: starch, microcrystalline cellulose and magnesium stearate. Proved by a pharmacodynamic test, the compound capsule has the functions of regulating blood fat and reducing the blood sugar, has the advantages of high safety, good stability and no obvious toxic or side effects and medicine resistant property, is used for treating type I diabetes and type II diabetes and is also used as a preventive medicament for reducing the blood sugar for long-term use.

The invention relates to a pharmaceutical composition for preventing and curing atherosclerosis. The pharmaceutical composition is prepared from an effective constituent and a pharmaceutically accepted ingredient, and is characterized in that the effective constituent is prepared from the following raw materials with the following weight ratio: geniposide to notoginsenoside R1 in a ratio of (1 to2) to (2 to 1). The pharmaceutical composition has the effects of lowering blood lipid level, inhibiting inflammation and reducing atherosclerotic plaques, and has a remarkable effect on improvement of the atherosclerosis.

The invention discloses a biomarker LINC01549 related to hepatocellular carcinoma and application thereof. The invention finds that expression of the LINC01549 is up-regulated in a patient suffering from the hepatocellular carcinoma for the first time, and after further verification through a large sample, a result shows that the LINC01549 as a detection substance has a relatively high positive detection rate; experiments further prove that the LINC01549 is related to proliferation, migration and invasion of hepatoma carcinoma cells, which indicates that the LINC01549 can be used as a medicinetarget for clinical treatment of the hepatocellular carcinoma.

The invention discloses an application of tanshinone IIA sulfonate sodium in preparation of a medicine. Blood is taken from the right ventricle 12 hours and 3 days after myocardial infarction, and the myocardial enzyme lactic dehydrogenase is detected. After the tanshinone IIA sulfonate sodium is used, LDH level begins to decrease after myocardial infarction for 12 hours, myocardial cell necrosis or injury begins to decrease, and significant difference is achieved in 3 days, so that the tanshinone IIA sulfonate sodium can significantly inhibit LDH level in plasma, especially LDH increase caused by myocardial cell necrosis or injury. Therefore, the tanshinone IIA sulfonate sodium can effectively inhibit the LDH level in a mouse body, and can be used for preparing antiepileptic drugs.

The invention discloses an application of a Guanxin salvia miltiorrhiza compound preparation in preparing a medicine for improving ventricular remodeling. The Guanxin salvia miltiorrhiza compound preparation is composed of 200 g of salvia miltiorrhiza, 200 g of pseudo-ginseng and 1.75 mL of dalbergiae odoriferae oil. The application comprises that for ventricular remodeling generated after acute ST-segment elevation myocardial infarction (STEMI) coronary artery recanalization, the Guanxin salvia miltiorrhiza compound preparation can effectively reduce levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase isoenzyme (CKMB) after STEMI coronary artery recanalization, improves systolic functions, reduces the area of myocardial fibrosis, and plays a major role in effectively improving ventricular remodeling.

The invention relates to the technical field of medicines, in particular to an application of nosiheptide to preparation of a periodontitis treatment medicine. The application proves that the nosiheptide has a treatment effect on a rat periodontitis model, can effectively improve the bone volume fraction, reduces the separation degree of bone trabecula, promotes osteogenesis, increases bone mass, inhibits inflammatory factors NF-K beta and TNF-alpha, inhibits the inflammatory cell level in periodontium, promotes fibroblast generation, promotes periodontium inflammation repair, facilitates periodontitis treatment, and does not have the side effects of enabling users to generate anorexia and influencing growth. The experimental result has clinical significance, and a new scheme is provided for clinical treatment of periodontitis.

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.